The most common question I receive about Selank is deceptively simple: how much should I take, and for how long? The answer requires understanding that Selank dosing is derived almost entirely from Russian clinical protocols and manufacturer guidance, not from dose-finding studies published in Western peer-reviewed journals. This creates an unusual situation where we have an approved medication dosing framework in one country, but limited independent pharmacokinetic data by international standards. Selank has a small body of Russian clinical research, mostly published in Russian, with no independent replication and no approval in the EU or the US.
Let me be direct about what we know and what we are extrapolating.
At a Glance
| Property | Value |
|---|---|
| What it is | A synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro): the immune peptide tuftsin with a stabilising Pro-Gly-Pro tail [5] |
| Evidence Level | Moderate (Russian clinical data); Limited (Western replication) |
| Best human evidence | One Russian comparison with medazepam (62 patients with generalised anxiety disorder or neurasthenia) reporting similar anxiolytic effects [1]; small biomarker studies [2] |
| Standard Dose | Russian label: 2 drops of the 0.15% solution per nostril, 3x daily (roughly 900 mcg a day). Community: 200-300 mcg intranasally, 2-3x daily |
| Cycle Length | Label: 14 days, repeatable after 1-3 weeks. Community: 4-6 weeks, often 1 month on, 1 month off (anecdotal) |
| Onset | Minutes (anxiolytic); days (cognitive) |
| Route | Intranasal (preferred) |
| Dependence Risk | None documented |
| Approval status | Registered as a medicine in Russia; not approved by the FDA, the EMA or Germany’s BfArM |
| Main risks | Limited and unreplicated safety data; FDA-flagged immunogenicity and impurity risk; product quality of grey-market sprays and vials |
| Anti-doping (WADA 2026) | Not named. S0 covers substances without approval by any governmental health authority; because selank is registered in Russia, athletes should get a ruling from their anti-doping organisation |
Protocol Table: Dose, Route, Timing and Basis
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
One row per use case. Basis: Label (registered product information), Practice protocol (reported by at least two independent compilations), Anecdotal (community reports only).
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Anxiety and asthenia (registered use in Russia) | 2 drops of the 0.15% solution (1.5 mg/mL) in each nostril | Intranasal | 3 times daily | 14 days; can be repeated after 1-3 weeks | Label (Selank nasal drops, Russian product information, RLS) |
| Daily anxiolytic or nootropic use, community standard | 200-300 mcg | Intranasal | 2-3 times daily | 4-6 weeks, often 1 month on, 1 month off | Anecdotal (Peptide Protocol Wiki, the most reported protocol) |
| Stronger anxiolytic effect | 600-900 mcg per day, split | Intranasal | 2-3 times daily | 2-4 weeks | Anecdotal (Peptide Protocol Wiki) |
| Subcutaneous use | 250-500 mcg (Peptide DB also lists 250 mcg twice daily) | SC | Once daily | 4-6 weeks, 5 days on, 2 days off | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| Low-dose maintenance | 100-200 mcg | Intranasal | Once daily | 4 weeks on, 4 weeks off | Anecdotal (Peptide Protocol Wiki) |
| Combined with Semax (“calm focus”) | Selank as above + Semax 200-600 mcg in the morning | Intranasal | Selank 2-3 times daily, Semax morning | 2-4 weeks | Anecdotal (Peptide Protocol Wiki, the most reported selank stack) |
The label gives drops, not micrograms. At 1.5 mg/mL, and assuming a 50 microlitre drop (the volume the Russian Semax label states for its own dropper; the Selank label does not give one), one drop holds about 75 mcg, so the label regimen comes to roughly 900 mcg a day.
Selank Dosage: What the Protocols Actually Say
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
If you are searching for Selank dosing information, you have probably encountered a range of numbers with little explanation of where they come from. Here is what the evidence shows.
The Russian Clinical Standard
Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is registered in Russia as 0.15% nasal drops. The label dosing (RLS product information) is:
- Concentration: 0.15% solution (1.5 mg/mL)
- Dose: 2 drops in each nostril (the label gives drops, not micrograms; assuming a 50 microlitre drop, each drop holds about 75 mcg, so one dosing is roughly 300 mcg)
- Frequency: 3 times daily
- Total daily dose: roughly 900 mcg
- Course duration: 14 days
- Repeat courses: the course can be repeated after 1-3 weeks if needed
The label also states 92.8% absolute bioavailability from the nasal mucosa, with the peptide detectable in plasma 30 seconds after dosing. This dosing framework comes from the Russian clinical studies behind Selank’s registration in Russia for generalized anxiety disorder and neurasthenia. The best-known study used standardized psychometric instruments (the Hamilton Anxiety Scale, Zung and CGI scales) and reported anxiolytic effects comparable to medazepam, a benzodiazepine, in 62 patients [1].
Pharmacokinetics: Why Intranasal Works
Selank is a heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) based on the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence that dramatically increases metabolic stability [5]. The intranasal route is preferred for several reasons:
Rapid absorption. Intranasal peptides bypass first-pass hepatic metabolism and access the CNS through the olfactory and trigeminal nerve pathways. Selank reaches detectable brain concentrations within minutes of nasal administration.
Improved bioavailability. Oral peptides are degraded by gastrointestinal proteases. Selank’s proline-rich sequence provides some protease resistance, but nasal delivery circumvents the problem entirely. A Russian animal study compared nasal and intraperitoneal delivery [8].
Practical compliance. A nasal spray is simpler than subcutaneous injection, which matters for a peptide taken multiple times daily over weeks.
The plasma half-life of Selank is short — estimates range from several minutes to approximately 30 minutes — which is why multiple daily administrations are required. However, downstream effects on gene expression (particularly BDNF upregulation and enkephalin metabolism) persist beyond the circulating half-life, which is why cognitive effects build over the course of treatment rather than appearing acutely.
What selank is and what it does
Selank was developed in Russia from tuftsin, a short peptide that is part of the immune system’s signalling. Adding Pro-Gly-Pro to the end makes the molecule more resistant to breakdown [5]. In Russian practice it is given as a nasal spray.
Animal and cell studies describe several possible mechanisms: effects on GABA-related gene expression [4][5], on stress-related behaviour and serotonin metabolism in rodents [3][6], and on BDNF in the rat hippocampus [7]. The Russian clinical study measured serum enkephalin activity alongside symptoms and reported changes during treatment [1]. In patients with anxiety disorders, a small study also reported shifts in cytokine balance during 14 days of treatment [2].
These mechanisms are plausible for an anxiolytic. They come mostly from one national research network and have not been mapped with the depth expected for a modern psychiatric drug.
The Evidence for Current Dosing
Preclinical
Rodent studies report anxiolytic-like behaviour under stress [3][6], effects on GABA-related gene expression in cell lines [4], and protection against alcohol-induced memory impairment linked to BDNF in rats [7]. Useful background, but rodent behavioural tests are weak predictors of human anxiety treatment.
Human
| Study | Design | n | What was studied | Finding | Certainty |
|---|---|---|---|---|---|
| Zozulia et al. 2008 [1] | Comparative clinical study (Russia) | 62 (30 selank, 32 medazepam) | Selank vs medazepam in GAD and neurasthenia | Similar anxiolytic effects on Hamilton, Zung and CGI scales; selank also reported as anti-asthenic | Low (small, single network, design details limited in the English abstract, unreplicated) |
| Uchakina et al. 2008 [2] | Biomarker study (Russia) | Small | 14 days of selank in anxiety-asthenic disorders | Changes in Th1/Th2 cytokine balance | Very low (surrogate markers) |
| Independent Western trials | None found | 0 | None | None | No evidence |
The limitation I must be transparent about: these studies were conducted in Russia, published largely in Russian-language journals, and have not been independently replicated. There is no placebo-controlled trial I could verify, no published dose-finding study, no long-term safety follow-up, and no head-to-head comparison with first-line anxiety treatments such as SSRIs or cognitive behavioural therapy. Across the published studies, no serious adverse events, physical dependence, tolerance, or withdrawal symptoms were reported at the approved dose range; the most commonly reported side effect was mild nasal irritation.
What I See When Coaching Patients
Selank at the lower end of the dosing range (200 mcg twice daily) is usually sufficient for those seeking anxiolytic effects. People consistently report a calming effect without sedation — a “clarity under stress” quality that distinguishes it from benzodiazepines and even from adaptogenic herbs.
The people who seem to benefit most from the higher end of the dosing range (400 mcg three times daily) are those with comorbid anxiety and cognitive complaints — people whose anxiety is not just emotional but is actively interfering with concentration, memory, and executive function. In these cases, the cognitive benefits at higher doses appear more pronounced.
What I tell patients: start at the lower dose. If you notice anxiolytic effects but want more cognitive support, titrate up in the second week. There is no evidence that higher doses produce proportionally better results, and the dose-response curve in animal data suggests a ceiling effect.
Practical Dosing Protocol
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
Standard Anxiolytic Protocol
| Parameter | Recommendation |
|---|---|
| Starting dose | 200 mcg per dose, split between nostrils, twice daily (morning and afternoon) |
| Upper range | 400 mcg per dose, three times daily; community reports for a stronger anxiolytic effect run at 600-900 mcg a day (Anecdotal) |
| Cycle length | 14 days per the Russian label; 4-6 weeks in community use (Anecdotal) |
| Rest period | 1-3 weeks per the label; community users often take 1 month off after 1 month on |
Timing Considerations
- Morning dose: Take within 30 minutes of waking. Selank does not cause sedation, so morning dosing supports both anxiolytic and cognitive function throughout the day.
- Afternoon dose: Take between 1-3 PM. This covers the natural cortisol dip and the period when anxiety-driven cognitive impairment often peaks.
- Third dose (if used): Take in the late afternoon, ideally before 5 PM. While Selank does not disrupt sleep, late-evening dosing is unnecessary given the short half-life and the fact that sleep is not the target.
Administration Technique
The effectiveness of intranasal peptides depends on proper administration:
- Clear nasal passages before administration
- Tilt head slightly forward (not back)
- Insert spray tip just inside the nostril, angling slightly toward the outer wall
- Actuate while gently inhaling through the nose
- Avoid sniffing forcefully — this drives the solution past the absorptive mucosa into the pharynx
- Wait 30-60 seconds before administering to the other nostril
Cycling Rationale
The nuance matters here. Selank does not produce tolerance in the traditional pharmacological sense — there is no receptor downregulation or tachyphylaxis documented in the literature. The recommendation to cycle is based on:
- Standard neuropeptide practice. Most peptide therapies are administered in courses rather than continuously, based on the principle that intermittent stimulation may maintain responsiveness better than continuous exposure.
- The original clinical trial design. The trials used 14-day courses, so our efficacy data applies to this duration. Longer continuous use has not been studied systematically.
- Clinical observation. Some people report that Selank’s anxiolytic effects are most pronounced in the first 10-14 days of each course, suggesting that periodic breaks may optimize the response.
Stacking Considerations
Selank is frequently discussed in the context of “stacking” with other nootropic peptides, particularly Semax. Here is what the evidence supports:
Selank + Semax. The most common combination. Selank provides anxiolytic and GABAergic modulation; Semax provides dopaminergic and nootropic stimulation. In practice, people who combine these often report the cognitive enhancement of Semax without the occasional overstimulation or anxiety that Semax can produce in sensitive individuals. There are no published interaction studies, but the mechanisms are complementary rather than overlapping. For variant-specific dosing of Semax — including the NA-Semax and NA-Semax Amidate forms that are commonly stacked with Selank — see the Semax Dosage and Nasal Protocol guide.
Selank + adaptogens. Combination with ashwagandha for stress and adrenal support or rhodiola has no published data, but the mechanisms do not conflict. In clinical observation, some people find the combination provides more sustained anxiolytic effects than either alone.
Selank + benzodiazepines. This is where caution is warranted. Selank modulates GABAergic transmission, and combining it with direct GABA receptor agonists (benzodiazepines) has not been studied for safety. I do not recommend this combination without physician oversight, particularly during benzodiazepine tapering — which is ironically one of the situations where Selank could theoretically be most useful. Any benzodiazepine taper belongs under medical supervision.
Known and theoretical risks
Selank has a clean short-term safety profile across the published data — no dependence, no sedation, no tolerance within the 14-day courses studied, and nasal irritation and mild headache as the most commonly reported adverse effects. What that data cannot show:
- Unknown long-term safety. Russian studies report good short-term tolerability, but small 14-day studies cannot detect uncommon or delayed harms.
- Immunogenicity and impurities. The FDA states that compounded drugs containing selank acetate may pose a risk of immune reactions due to aggregation and peptide-related impurities, and that it lacks important information about safety in humans [9].
- Immune effects. Selank derives from an immune peptide and changed cytokine markers in a small study [2]. In people with autoimmune disease or on immunosuppressive treatment, those effects are untested.
- Interactions. Combining selank with benzodiazepines, alcohol, other sedatives or other nasal “nootropic” peptides has not been studied.
- Grey-market product quality. Sprays and vials sold online as “research peptides” are not made to pharmaceutical standards. In test purchases of semaglutide from illegal online sellers, purity was 7.7 to 14.4 percent against a 99 percent label claim, with endotoxin in every sample [10]. Nasal products can also be contaminated.
- Delayed care. Self-treating anxiety can postpone diagnosis of depression, thyroid disease, substance use or other treatable causes.
Contraindications and cautions:
- Pregnancy and lactation (no safety data)
- Active nasal infection or significant nasal inflammation (impairs absorption)
- Concomitant use of immunosuppressants (Selank has immunomodulatory properties via its tuftsin origin)
- Patients with autoimmune conditions should consult their physician, as immune modulation strategies could theoretically influence disease activity
Regulatory status
- United States (FDA). Selank is not an approved drug. On the FDA page “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks” (content current as of 22 April 2026), selank acetate (TP-7) is listed among substances previously in category 2 whose nominations were withdrawn. It is not on the 503A bulks list and not in category 1 (“under evaluation”) on the FDA list updated 14 May 2026 [9].
- EU and Germany. Not authorised by the EMA or the BfArM. Selling a vial as “research use only” avoids drug approval; it says nothing about whether the contents are safe or tested in people.
- Russia. Registered as a nasal medicine. Its label has not been reviewed by EU or US regulators.
- Sport (WADA 2026). Not named on the Prohibited List. S0 covers pharmacological substances with no current approval by any governmental health authority; a substance approved only in one country may be treated differently, so athletes should obtain a ruling before use [11].
When to talk to a physician
If anxiety affects your sleep, work or relationships, see a physician or psychotherapist. Cognitive behavioural therapy and SSRIs or SNRIs have strong evidence for generalised anxiety disorder, and a physician can also check for thyroid problems, medication effects or depression. If you are tapering off a benzodiazepine, do that only with medical supervision.
The Bottom Line
The Russian label gives 2 drops of the 0.15% solution in each nostril three times a day (roughly 900 mcg a day) for 14 days, repeatable after 1-3 weeks. Community users mostly take 200-300 mcg two or three times a day for 4-6 weeks. The evidence supporting this protocol is moderate — it is based on approved clinical use in Russia and consistent preclinical data, but it lacks independent Western replication, and Selank is not approved by the FDA, the EMA or the BfArM. The short-term safety profile is good, with no dependence, tolerance, or significant adverse effects documented. Start at the lower dose, assess response over the first week, and titrate based on whether anxiolytic effects alone are sufficient or cognitive support is also desired.
This is what the research actually says — not a miracle anxiolytic, but a well-tolerated peptide with a specific niche in anxiety management that does not compromise cognitive function.
Back to Selank Overview | All Peptide Articles
References
- Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18454096.
- Uchakina ON, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders [in Russian]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18577961.
- Kozlovskaya MM, et al. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003. PMID: 14969422.
- Filatova E, et al. GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017. PMID: 28293190.
- Vyunova TV, et al. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein Pept Lett. 2018. PMID: 30255741.
- Seredenin SB, et al. The characteristics of the anxiolytic action of tuftsin and its analog TP-7 on behavior and serotonin metabolism [in Russian]. Eksp Klin Farmakol. 1995. PMID: 8704608.
- Kolik LG, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019. PMID: 31625062.
- Vasil’eva EV, et al. Comparison of pharmacological effects of heptapeptide Selank after intranasal and intraperitoneal administration [in Russian]. Eksp Klin Farmakol. 2016. PMID: 29787664.
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026); Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (updated 14 May 2026).
- Ashraf AR, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024. PMID: 39509151.
- World Anti-Doping Agency. The 2026 Prohibited List (valid 1 January 2026), section S0.
Disclaimer: This article is for informational purposes only and is not a prescription or individual medical advice. It reflects one physician’s reading of the research and of practice. Selank is registered in Russia but is not approved by the FDA, the EMA or the BfArM. Consult a qualified physician before beginning any peptide protocol.